Inflammatory Markers Correlate with Lymphocytes Infiltrating and Predict Immunotherapy Prognosis for Esophageal Cancer

Overview

Journal Future Oncol

Specialty Oncology

Date 2024 Nov 12

PMID 39530611

Authors

Bei Wang

Zixuan Wang

Kun Wang

Zhongming Shao

Haitao Chen

Lincheng Xu

Yan Pan

Mingyue Zheng

Wei Geng

Chuanhai Xu

Affiliations

Soon will be listed here.

Abstract

To investigate the prognostic value of inflammatory markers in esophageal squamous cell carcinoma (ESCC) patients treated with immune checkpoint inhibitors (ICIs). The infiltration of CD3 and CD8 T cells in tissue microarrays from 180 patients who underwent radical esophagectomy was detected using immunohistochemistry. A separate cohort of 351 patients with metastatic/recurrent or unresectable ESCC treated with ICIs was enrolled for further investigation. The overall survival difference among groups was assessed using Kaplan-Meier analysis. Cox proportional hazards models were employed to investigate the prognostic impact of the inflammatory markers, along with other factors. Decreased inflammation was found to be associated with increased CD3 and CD8 T-cell infiltration and a better prognosis. Then, the value of inflammatory markers in predicting survival in 351 ESCC patients receiving immunotherapy was validated. Ultimately, the systemic immune-inflammation index was identified as an independent prognostic factor for overall survival. Additionally, the patients with no distant organ metastasis, or treated by first-line immunotherapy combined with concurrent chemoradiotherapy can considerably prolong survival. Inflammation is associated with the level of tumor infiltrating lymphocytes and that the systemic immune-inflammation index is an effective prognostic predictor for ESCC patients treated with ICIs.

References

Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L . Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022; 377:e068714. PMC: 9016493. DOI: 10.1136/bmj-2021-068714. View

Chen X, Meng F, Jiang R . Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11:746976. PMC: 8660071. DOI: 10.3389/fonc.2021.746976. View

Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699. View

Sun J, Shen L, Shah M, Enzinger P, Adenis A, Doi T . Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021; 398(10302):759-771. DOI: 10.1016/S0140-6736(21)01234-4. View

Akgul O, Cetinkaya E, Yalaza M, Ozden S, Tez M . Prognostic efficacy of inflammation-based markers in patients with curative colorectal cancer resection. World J Gastrointest Oncol. 2017; 9(7):300-307. PMC: 5534398. DOI: 10.4251/wjgo.v9.i7.300. View

Ocana A, Nieto-Jimenez C, Pandiella A, Templeton A . Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer. 2017; 16(1):137. PMC: 5558711. DOI: 10.1186/s12943-017-0707-7. View

Ruiz-Ranz M, Lequerica-Fernandez P, Rodriguez-Santamarta T, Suarez-Sanchez F, Lopez-Pintor R, Garcia-Pedrero J . Prognostic implications of preoperative systemic inflammatory markers in oral squamous cell carcinoma, and correlations with the local immune tumor microenvironment. Front Immunol. 2022; 13:941351. PMC: 9360320. DOI: 10.3389/fimmu.2022.941351. View

Lalani A, Xie W, Martini D, Steinharter J, Norton C, Krajewski K . Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018; 6(1):5. PMC: 5776777. DOI: 10.1186/s40425-018-0315-0. View

Wang H, Ding Y, Li N, Wu L, Gao Y, Xiao C . Prognostic Value of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Combined Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Stage IV Advanced Gastric Cancer. Front Oncol. 2020; 10:841. PMC: 7317009. DOI: 10.3389/fonc.2020.00841. View

10.

Guo J, Yang Q, Jiang Q, Gu L, Lin H, Guo L . Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor. Nutrients. 2023; 15(19). PMC: 10574520. DOI: 10.3390/nu15194262. View

11.

Placke T, Orgel M, Schaller M, Jung G, Rammensee H, Kopp H . Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2011; 72(2):440-8. DOI: 10.1158/0008-5472.CAN-11-1872. View

12.

Fornarini G, Rebuzzi S, Banna G, Calabro F, Scandurra G, De Giorgi U . Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. ESMO Open. 2021; 6(3):100118. PMC: 8134706. DOI: 10.1016/j.esmoop.2021.100118. View

13.

Kopp H, Placke T, Salih H . Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009; 69(19):7775-83. DOI: 10.1158/0008-5472.CAN-09-2123. View

14.

Wang J, Jia Y, Wang N, Zhang X, Tan B, Zhang G . The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma. J Transl Med. 2014; 12:7. PMC: 3895663. DOI: 10.1186/1479-5876-12-7. View

15.

Baek J, Cha H, Moon Y, Kim L, Kwak S, Park E . A Systemic Immune Inflammation Index and PD-L1 (SP142) Expression as a Potential Combined Biomarker of the Clinical Benefit of Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer. J Clin Med. 2024; 13(5). PMC: 10932321. DOI: 10.3390/jcm13051521. View

16.

Smith H, Kang Y . The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl). 2013; 91(4):411-29. PMC: 3697909. DOI: 10.1007/s00109-013-1021-5. View

17.

Ying H, Deng Q, He B, Pan Y, Wang F, Sun H . The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol. 2014; 31(12):305. DOI: 10.1007/s12032-014-0305-0. View

18.

Morgan E, Soerjomataram I, Rumgay H, Coleman H, Thrift A, Vignat J . The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology. 2022; 163(3):649-658.e2. DOI: 10.1053/j.gastro.2022.05.054. View

19.

Robert C . A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020; 11(1):3801. PMC: 7393098. DOI: 10.1038/s41467-020-17670-y. View

20.

Stares M, Ding T, Stratton C, Thomson F, Baxter M, Cagney H . Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer. ESMO Open. 2022; 7(2):100445. PMC: 9058907. DOI: 10.1016/j.esmoop.2022.100445. View